ImmunoGen, Inc. (NASDAQ:IMGN) gapped down before the market opened on Friday . The stock had previously closed at $8.66, but opened at $8.36. ImmunoGen shares last traded at $8.07, with a volume of 5,488,867 shares trading hands.

A number of research firms have recently weighed in on IMGN. Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 price target (up previously from $8.00) on shares of ImmunoGen in a report on Wednesday. Cowen and Company reaffirmed a “hold” rating on shares of ImmunoGen in a report on Tuesday. Leerink Swann reaffirmed a “buy” rating on shares of ImmunoGen in a report on Tuesday. Cantor Fitzgerald reaffirmed a “hold” rating on shares of ImmunoGen in a report on Tuesday. Finally, BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 26th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $8.01.

The company’s market cap is $723.05 million. The company’s 50-day moving average price is $6.29 and its 200-day moving average price is $4.84.

ImmunoGen (NASDAQ:IMGN) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.07. The company had revenue of $39.02 million for the quarter, compared to analyst estimates of $30.59 million. During the same quarter in the previous year, the company posted ($0.53) earnings per share. ImmunoGen’s revenue for the quarter was up 426.6% on a year-over-year basis. Equities research analysts expect that ImmunoGen, Inc. will post ($0.74) EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in IMGN. Arrowstreet Capital Limited Partnership bought a new position in shares of ImmunoGen during the second quarter worth about $102,000. Gould Asset Management LLC CA bought a new position in shares of ImmunoGen during the second quarter worth about $107,000. Intl Fcstone Inc. bought a new position in shares of ImmunoGen during the second quarter worth about $115,000. Aperio Group LLC raised its position in shares of ImmunoGen by 45.1% in the second quarter. Aperio Group LLC now owns 16,797 shares of the biotechnology company’s stock worth $119,000 after buying an additional 5,221 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of ImmunoGen during the second quarter worth about $126,000. Institutional investors own 84.64% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ImmunoGen, Inc. (IMGN) Shares Gap Down to $8.36” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/01/immunogen-inc-imgn-shares-gap-down-to-8-36.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.